Sildenafil citrate (VIAGRA®) in the treatment of erectile dysfunction: Analysis of two flexible dose-escalation studies

International Journal of Clinical Practice, Supplement

Volumn , Issue 102, 1999, Pages 10-12

  Feldman, R ^a   Meuleman, E J H ^b   Steers, W ^c  

^a Academisch Ziekenhuis ^*

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; PIPERAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VISUAL DISORDER; DOUBLE BLIND PROCEDURE; IMPOTENCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0033138733     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (1)

1. Boolell M, Allen MJ, Ballard SA et al. Sildenafil: an orally active type 5 cyclic GMP-specific phos-phodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8(2): 47-52.